<DOC>
	<DOC>NCT01519882</DOC>
	<brief_summary>This is a phase 4 study to evaluate with Polysomnography (PSG) and subjective measures the effect of Rotigotine on sleep efficiency, maintenance, insomnia, nocturnal akinesia and night-time movement in bed, in patients with advanced Parkinson's disease.</brief_summary>
	<brief_title>Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Advanced Parkinson's disease (ie, takes Levodopa (LDOPA)) Hoehn and Yahr stage score of 2 to 4 Subject has sleepmaintenance insomnia Significant skin disease that would make transdermal drug use inappropriate Subject received therapy with controlledrelease Levodopa (LDOPA), entacapone or StalevoÂ® within 28 days prior to the Baseline Visit or has received therapy with Tolcapone Atypical Parkinsonian syndromes Previous diagnosis of Narcolepsy, Sleep Apnoea Syndrome, significant Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD), moderate to severe Restless Legs Syndrome (RLS) or Periodic Limb Movement Disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
	<keyword>Polysomnography</keyword>
	<keyword>Sleep efficiency</keyword>
	<keyword>Advanced Idiopathic Parkinson's Disease</keyword>
	<keyword>Sleep Disorder</keyword>
</DOC>